Sun Pharmaceutical Industries Ltd. said on Saturday it proposed to fully acquire Israel-based Taro Pharmaceutical Industries Ltd. through a reverse triangular merger.
The Mumbai-based drug major said it has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares for a purchase price of USD 38 per ordinary share in cash.
Sun Pharma currently owns a 78.48% stake in Taro.
"We envisage the proposed transaction to be consummated in the form of a reverse triangular merger under the Israeli Companies Law, 1999 and practice," Sun Pharma said in a regulatory filing.
The purchase price represents a premium of 31.2% over Taro's closing price on May 25, 2023, a 41.5% premium over Taro's average closing price in the last 60 days and a compelling liquidity opportunity for Taro's shareholders, it added.
Under the indicative proposal, post the acquisition, Taro will become a wholly-owned subsidiary of Sun Pharma and will be delisted from NYSE.
RECOMMENDED FOR YOU
Sun Pharma - ‘Specialty’ Way Of Driving Growth Prospects: Motilal Oswal
Apr 24, 2024
Sun Pharma-FDA: Regulatory Concerns At Dadra facility Can Dent Sentiment, Say Analysts
Apr 18, 2024
Sun Pharma At Over Three-Week Low After FDA's Action On Dadra Plant
Apr 12, 2024
Vodafone Idea Shares Can Slide 60% On Falling Subscriber Base, Says CLSA
Apr 10, 2024
POPULAR